Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
Public ClinicalTrials.gov record NCT00183261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.
Study identification
- NCT ID
- NCT00183261
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Interventions
- MRKAd5 HIV-1 gag/pol/nef Biological
- MRKAd5 HIV-1 gag/pol/nef placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2006
- Primary completion
- Jul 31, 2007
- Completion
- Sep 30, 2010
- Last update posted
- Oct 31, 2021
2006 – 2010
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ucsd Aiedrp | San Diego | California | 92103 | — |
| Ucsf Aiedrp | San Francisco | California | 94110 | — |
| LA Biomedical Research Institute at Harbor-UCLA AIEDRP | Torrance | California | — | — |
| Univ. of Colorado Health Sciences Ctr. AIEDRP | Denver | Colorado | 80220 | — |
| Fenway Community Health Ctr. CRS | Boston | Massachusetts | 02115 | — |
| Washington U CRS | St Louis | Missouri | 63110 | — |
| Beth Israel Med. Ctr., ACTU | New York | New York | 10003 | — |
| Aaron Diamond AIDS Research Ctr. AIEDRP | New York | New York | 10016 | — |
| Unc Aids Crs | Chapel Hill | North Carolina | 27514 | — |
| UNC, Chapel Hill AIEDRP | Chapel Hill | North Carolina | 27599 | — |
| Duke Univ. Med. Ctr. Adult CRS | Durham | North Carolina | 27710 | — |
| Dumc Aiedrp | Durham | North Carolina | — | — |
| The Miriam Hosp. ACTG CRS | Providence | Rhode Island | 02906 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00183261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2021 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00183261 live on ClinicalTrials.gov.